Home > Insider Trading > Filing (0001567619-21-017389)

Filing Details

Accession Number:: 0001567619-21-017389
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-09-21 16:03:26
Reporting Period:: 2021-09-17

Accepted Time:: 2021-09-21 16:03:26
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1863127	Tyra Biosciences Inc.	TYRA	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1583977	Cormorant Asset Management, Lp	200 Clarendon Street, 52Nd Floor Boston MA 02116	No	No	No	Yes
1599214	Bihua Chen	C/O Cormorant Asset Management, Llc 200 Clarendon Street, 52Nd Floor Boston MA 02116	Yes	No	No	Yes
1618442	Cormorant Global Healthcare Master Fund, Lp	200 Clarendon Street, 52Nd Floor Boston DC 02116	No	No	No	Yes
1817320	Cormorant Private Healthcare Fund Iii Lp	200 Clarendon Street, 52Nd Floor Boston MA 02116	No	No	No	Yes

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-09-17	757,432	$0.00	757,432	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2021-09-17	312,500	$16.00	1,069,932	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Convertible Preferred Stock	Disposition	2021-09-17	757,432	$0.00	757,432	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect

Footnotes

Shares of Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering.
Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund III, LP ("Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
Represents (i) 165,877 shares held by the Master Fund, (ii) 578,111 shares held by Fund III, and (iii) 13,444 shares held by the Account.
Shares reported herein as purchased on September 17, 2021 represent 312,500 shares purchased by the Master Fund.
The Series B Convertible Preferred Stock represented, on an as-converted basis, (i) 165,877 shares held by the Master Fund, (ii) 578,111 shares held by Fund III, and (iii) 13,444 shares held by the Account.